APA (7th ed.) Citation

W, L., J, X., Y, L., X, L., J, Y., & W, Z. (2024). Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International journal of clinical pharmacy, 46(3), 776. https://doi.org/10.1007/s11096-024-01728-8

Chicago Style (17th ed.) Citation

W, Lin, Xu J, Liao Y, Lin X, Yang J, and Zhuang W. "Author Correction: Assessing Safety Concerns of Interstitial Lung Disease Associated with Antibody-drug Conjugates: A Real-world Pharmacovigilance Evaluation of the FDA Adverse Event Reporting System." International Journal of Clinical Pharmacy 46, no. 3 (2024): 776. https://doi.org/10.1007/s11096-024-01728-8.

MLA (9th ed.) Citation

W, Lin, et al. "Author Correction: Assessing Safety Concerns of Interstitial Lung Disease Associated with Antibody-drug Conjugates: A Real-world Pharmacovigilance Evaluation of the FDA Adverse Event Reporting System." International Journal of Clinical Pharmacy, vol. 46, no. 3, 2024, p. 776, https://doi.org/10.1007/s11096-024-01728-8.